Tango Therapeutics (TNGX) to Release Quarterly Earnings on Tuesday

Key Points

• Tango Therapeutics is set to release its Q2 2025 earnings report on August 5th, with analysts predicting a loss of ($0.35) per share and revenue of $6.41 million.
• The company's previous earnings report showed a loss of ($0.36) per share, missing expectations, and a revenue of $5.39 million, which was lower than the projected $6.73 million.
• Institutional investors have increased their stakes, with 78.99% of the company's stock now owned by hedge funds and other institutional investors.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Tuesday, August 5th. Analysts expect Tango Therapeutics to post earnings of ($0.35) per share and revenue of $6.41 million for the quarter.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.02). Tango Therapeutics had a negative net margin of 322.67% and a negative return on equity of 62.75%. The firm had revenue of $5.39 million during the quarter, compared to analyst estimates of $6.73 million. On average, analysts expect Tango Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tango Therapeutics Stock Down 2.3%

Shares of NASDAQ TNGX traded down $0.15 during mid-day trading on Wednesday, hitting $6.30. 3,189,225 shares of the company were exchanged, compared to its average volume of 1,492,807. The firm has a market cap of $682.86 million, a price-to-earnings ratio of -5.16 and a beta of 1.63. Tango Therapeutics has a 1-year low of $1.03 and a 1-year high of $12.02. The stock has a 50 day simple moving average of $4.92 and a 200-day simple moving average of $3.00.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "buy" rating and set a $13.00 price objective on shares of Tango Therapeutics in a research report on Monday, April 14th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tango Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $10.50.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd increased its holdings in shares of Tango Therapeutics by 139.7% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company's stock valued at $35,000 after acquiring an additional 15,037 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Tango Therapeutics by 138.8% during the 1st quarter. Invesco Ltd. now owns 70,517 shares of the company's stock valued at $97,000 after acquiring an additional 40,983 shares during the last quarter. AQR Capital Management LLC acquired a new position in shares of Tango Therapeutics during the 1st quarter valued at about $195,000. Jane Street Group LLC increased its holdings in shares of Tango Therapeutics by 270.6% during the 1st quarter. Jane Street Group LLC now owns 352,897 shares of the company's stock valued at $483,000 after acquiring an additional 257,668 shares during the last quarter. Finally, Woodline Partners LP grew its holdings in Tango Therapeutics by 28.3% in the 1st quarter. Woodline Partners LP now owns 506,188 shares of the company's stock valued at $693,000 after buying an additional 111,791 shares during the last quarter. 78.99% of the stock is owned by institutional investors and hedge funds.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.